US00534A1025 - Common Stock
ADAGIO THERAPEUTICS INC
NASDAQ:ADGI (9/12/2022, 7:13:11 PM)
After market: 4.52 -0.12 (-2.59%)4.64
+0.04 (+0.87%)
Adagio Therapeutics, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is headquartered in Waltham, Massachusetts and currently employs 101 full-time employees. The company went IPO on 2021-08-06. The firm is focused on the discovery, development and commercialization of differentiated products for the prevention and treatment of infectious diseases. Its product candidate, adintrevimab, for the prevention and treatment of coronavirus disease 2019 (COVID-19), the disease caused by the virus SARS-CoV-2 and its variants. The firm has a clinical program with a Phase I healthy volunteer single ascending-dose escalation study to establish the safety, pharmacokinetics, and serum virus neutralizing antibody titers of adintrevimab. Its Phase II/III global clinical trial, EVADE, evaluates adintrevimab in the prevention of symptomatic COVID-19 in two separate populations: individuals with known exposure to a person with laboratory-confirmed SARS-CoV-2 infection, also known as post-exposure prophylaxis, and individuals who are at increased risk for SARS-CoV-2 infection, also known as pre-exposure prophylaxis.
ADAGIO THERAPEUTICS INC
1601 Trapelo Road, Suite 178
Waltham MASSACHUSETTS
P: 17818190080.0
Employees: 101
Website: https://adagiotx.com/
Integrated discovery platform is producing a stream of candidate antibodies demonstrating broad in vitro neutralization against past variants of concern...
Here you can normally see the latest stock twits on ADGI, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: